ClinicalTrials.gg
CompletedNCT02454478Updated Mar 19, 2019Results posted

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

A Phase 1 interventional study of Lenvatinib and Everolimus in Carcinoma, Renal Cell, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing lenvatinib in Carcinoma, Renal Cell — 13 open to participants now, 17 under way, 2 of them phase 3. lenvatinib · Carcinoma, Renal Cell.

Enrollment
29th of 30
7 · median 30
Started
2015
the only one that year
Phase 1
4 of 30
1 open now
Registered
2nd of 30
by date
Lead sponsor
1 of 30
Eisai Co., Ltd.

Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, this one is the 29th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 2nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

13 of the 30 studies testing lenvatinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing lenvatinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • lenvatinib
  • Everolimus
  • Carcinoma
  • Unresectable advanced renal cell carcinoma
  • Metastatic renal cell carcinoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary agreement to provide written of this study.
  2. Willing and able to comply with all aspects of the protocol after being fully informed of the content.
  3. Males or females aged greater than or equal to 20 years at the time of informed consent.
  4. Histological or cytological confirmation of RCC.
  5. Participants must have confirmed diagnosis of unresectable advanced and/or RCC.
  6. Disease progression following vascular endothelial growth factor (VEGF) targeted therapy.
  7. Performance Status (ECOG-PS) of 0 to 1.
  8. Adequately controlled blood pressure with or without the use of antihypertensive agents.
  9. Participants with adequate function of major organs.
  10. Adequate blood coagulation function, defined as (INR) less than or equal to 1.5.
  11. Survival expectation of 3 months or longer after study enrollment.
  12. Participants with adequate from the end of prior treatment to the start of study drug administration.
  13. Females of must not have had unprotected sexual intercourse within 28 days before participant registration and must agree to use a highly effective method of throughout the entire study period and for 30 days after final administration of drug. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during this study period or for 30 days after investigational drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before administration and must continue to use the same contraceptive during this study and for 30 days after investigational drug discontinuation.
  14. Male participants and their female partners must meet the criteria above.

Exclusion criteria

Exclusion Criteria:

  1. Participants with central nervous system (CNS) are not eligible, unless they have completed local therapy and have discontinued the use of for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of must be stable for at least 4 weeks before starting study treatment.
  2. Prior exposure to lenvatinib.
  3. Participants who have not recovered from toxicities to less than or equal to Grade 1 as a result of prior anticancer therapy, except alopecia.
  4. Major surgery within 3 weeks prior to the first dose of lenvatinib.
  5. Participants with a urine protein greater than or equal to 1 gram per 24 hours (g/24 hours).
  6. Uncontrollable diabetes as defined by fasting glucose greater than 1.5* (ULN).
  7. Fasting total cholesterol greater than 7.75 millimole per liter (mmol/L) (greater than 300 milligram per decilitre [mg/dL]).
  8. Fasting triglycerides greater than 2.5 * ULN.
  9. Any condition that might affect the absorption of lenvatinib and/or everolimus.
  10. Significant cardiovascular impairment.
  11. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic monitoring.
  12. Active hemoptysis.
  13. Active infections that require systemic treatment.
  14. (HIV) positive.
  15. virus (HBV).
  16. A history of interstitial pneumonia with clinical manifestation or as confirmed by means of diagnostic imaging.
  17. Medical need for the continued use of potent or moderate inhibitors of cytochrome P450 3A () or P-gp, or potent or moderate inducer of CYP3A.
  18. Known intolerance to lenvatinib (or any of the ) or known to everolimus (or any of the excipients) or rapmycins (sirolimus, temsirolimus and so on).
  19. Alcohol or drug dependency or abuse, inability to comply with every aspects of the study protocol, or any physical or mental conditions that in the opinion of the investigators would preclude the participant's participation in the study.
  20. Females who are pregnant or breastfeeding (not eligible even she discontinues breastfeeding).
  21. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Lenvatinib plus Everolimus

    Drug: Lenvatinib · Drug: Everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)

    DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).

    Time frame: From first dose of study drug up to Cycle 1 Day 28 (Cycle length=28 days)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Levatinib and Everolimus

    Time frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)

  2. Css,Max: Maximum Observed Plasma Concentration at Steady State for Levatinib and Everolimus

    Time frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)

  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Levatinib and Everolimus

    Time frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)

  4. Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for Levatinib and Everolimus

    Time frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)

  5. AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Levatinib and Everolimus

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)

  6. Number of Participants With Best Overall Response (BOR)

    BOR included complete response (CR), partial response (PR), stable disease (SD), and PD (progressive disease). BOR was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)

  7. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved BOR of CR or PR. ORR was assessed using RECIST 1.1.

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)

  8. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who achieved BOR of CR, PR, or SD. DCR was assessed based on RECIST 1.1.

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)

  9. Number of Participants With the Minimum Percent Change From Baseline in the Sum of Diameters of Target Lesions

    Time frame: Baseline up to first tumor assessment at which diameter of target lesions were available (up to approximately 23 months)

07

Results

Posted Feb 8, 2019

Participant flow

Participants took part in the study at 3 sites in Japan from 01 July 2015 to 29 May 2017.

Participant flow — Overall Study
MilestoneLenvatinib 18 mg + Everolimus 5 mg
Started7
Completed6
Not completed1
Withdrew: Incomplete dlt evaluation1

Outcome measures

PrimaryNumber of Participants Who Experienced Any Dose Limiting Toxicity (DLT)

DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).

Time frame:
From first dose of study drug up to Cycle 1 Day 28 (Cycle length=28 days)
Reported as:
Number · participants
Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)
participantsLenvatinib 18 mg + Everolimus 5 mg
Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)0
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsLenvatinib 18 mg + Everolimus 5 mg
TEAE7
SAE3
SecondaryCmax: Maximum Observed Plasma Concentration for Levatinib and Everolimus
Time frame:
Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Levatinib and Everolimus
nanogram per milliliter (ng/mL)Lenvatinib 18 mg + Everolimus 5 mg
Lenvatinib: Cycle 1 Day 1289 ± 136
Everolimus: Cycle 1 Day 139.1 ± 18.7
SecondaryCss,Max: Maximum Observed Plasma Concentration at Steady State for Levatinib and Everolimus
Time frame:
Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Reported as:
Mean · ng/mL
Css,Max: Maximum Observed Plasma Concentration at Steady State for Levatinib and Everolimus
ng/mLLenvatinib 18 mg + Everolimus 5 mg
Lenvatinib: Cycle 1 Day 15257 ± 112
Everolimus: Cycle 1 Day 1541.5 ± 19.3
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Levatinib and Everolimus
Time frame:
Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Levatinib and Everolimus
hourLenvatinib 18 mg + Everolimus 5 mg
Lenvatinib: Cycle 1 Day 13.87 (0.95 to 3.87)
Everolimus: Cycle 1 Day 10.92 (0.82 to 1.10)
SecondaryTss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for Levatinib and Everolimus
Time frame:
Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Reported as:
Median · hour
Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for Levatinib and Everolimus
hourLenvatinib 18 mg + Everolimus 5 mg
Lenvatinib: Cycle 1 Day 153.77 (1.88 to 4.08)
Everolimus: Cycle 1 Day 150.97 (0.83 to 3.97)
SecondaryAUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Levatinib and Everolimus
Time frame:
Cycle 1 Day 1 and Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Reported as:
Mean · hour * nanogram per milliliter (h*ng/mL)
AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Levatinib and Everolimus
hour * nanogram per milliliter (h*ng/mL)Lenvatinib 18 mg + Everolimus 5 mg
Lenvatinib: Cycle 1 Day 12770 ± 1090
Everolimus: Cycle 1 Day 1211 ± 115
Lenvatinib: Cycle 1 Day 153220 ± 1080
Everolimus: Cycle 1 Day 15401 ± 128
SecondaryNumber of Participants With Best Overall Response (BOR)

BOR included complete response (CR), partial response (PR), stable disease (SD), and PD (progressive disease). BOR was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1

Time frame:
From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Reported as:
Number · participants
Number of Participants With Best Overall Response (BOR)
participantsLenvatinib 18 mg + Everolimus 5 mg
CR0
PR5
SD1
PD1
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who achieved BOR of CR or PR. ORR was assessed using RECIST 1.1.

Time frame:
From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsLenvatinib 18 mg + Everolimus 5 mg
Objective Response Rate (ORR)71.4
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who achieved BOR of CR, PR, or SD. DCR was assessed based on RECIST 1.1.

Time frame:
From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsLenvatinib 18 mg + Everolimus 5 mg
Disease Control Rate (DCR)85.7
SecondaryNumber of Participants With the Minimum Percent Change From Baseline in the Sum of Diameters of Target Lesions
Time frame:
Baseline up to first tumor assessment at which diameter of target lesions were available (up to approximately 23 months)
Reported as:
Number · participants
Number of Participants With the Minimum Percent Change From Baseline in the Sum of Diameters of Target Lesions
participantsLenvatinib 18 mg + Everolimus 5 mg
Less than or equal to (<=) -30%5
Greater than (>) -30% to less than (<) 20%1
Greater than or equal to (>=) 20%1

Adverse events

Collected over Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 18 mg + Everolimus 5 mg0/7 (0%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventLenvatinib 18 mg + Everolimus 5 mg
Decreased appetiteMetabolism and nutrition disorders1/7
DehydrationMetabolism and nutrition disorders1/7
Spinal column stenosisMusculoskeletal and connective tissue disorders1/7
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/7
Most frequent other events
Showing 10 of 86
Most frequent other events
EventLenvatinib 18 mg + Everolimus 5 mg
ThrombocytopeniaBlood and lymphatic system disorders7/7
Decreased appetiteMetabolism and nutrition disorders6/7
HypertriglyceridaemiaMetabolism and nutrition disorders6/7
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders6/7
LeukopeniaBlood and lymphatic system disorders5/7
LymphopeniaBlood and lymphatic system disorders5/7
NeutropeniaBlood and lymphatic system disorders5/7
FatigueGeneral disorders5/7
Oedema peripheralGeneral disorders5/7
Blood cholesterol increasedInvestigations5/7

Baseline characteristics

The safety analysis set was the group of participants who received at least 1 dose of lenvatinib.

Age, Continuous
Age, Continuous(years)Lenvatinib 18 mg + Everolimus 5 mg
Mean65.7 ± 6.29
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 18 mg + Everolimus 5 mg
Female1
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 18 mg + Everolimus 5 mg
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 18 mg + Everolimus 5 mg
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Eisai Trial Site #1
    Chiba, Japan
  • Eisai Trial Site #1
    Tokyo, Japan
  • Eisai Trial Site #2
    Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in May 2017, 22 months.

Results were first posted in Feb 2019, 1 year 8 months after primary completion.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 22 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 27, 2015
StartActual
Jul 1, 2015
Primary completionActual
May 29, 2017
CompletionActual
May 29, 2017
Results first posted
Feb 8, 2019
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02454478
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Jul 1, 2015
Primary completion
May 29, 2017
Completion
May 29, 2017
Results posted
Feb 8, 2019
Last update
Mar 19, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Everolimus

Start the discussion